Why is Onesource Specialty Pharma Share Price Falling? Check Next Share Price Target 

 Click Here – Get Free Investment Predictions

As per the recent Onesource Specialty Pharma share price of ₹1,247.60, it underperformed its sector by 5.20% over the past day. The stock has declined by 13.98% over the past 5 days and declined by 3.61% over the past month. The company’s financial performance in the latest quarter underscores its enduring operational resilience. These figures highlight a period of volatility and consolidation within a broader trading brand. 

The stock remains liquid enough for trading, but its moving averages suggest a mixed outlook, and even the stock’s recent performance. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning underscores the prevailing negative momentum and suggests that the stock is navigating a challenging phase in terms of price stability.   

Key Reasons Behind Onesource Specialty Pharma Share Price Falling 

Tap to Access Best Research Pieces

There are several reasons behind the Onesource Specialty Pharma share price falling, including Weak Q3 FY26 Financial Results, Delay in Semaglutide Approval (Canada), Revenue Shortfall Due to Client Approval Delays, Bearish Technical Indicators, and  Downgrade by Analysts / Strong Sell Rating.      

Below are the key reasons behind the Onesource Specialty Pharma share price fall: 

• Weak Q3 FY26 Financial Results: One of the main reasons for the fall was the company’s poor quarterly performance. OneSource reported a net loss of around ₹47-88 crore, unlike the profits earned in earlier quarters, along with a sharp 26% fall in revenue.
• Delay in Semaglutide Approval (Canada): However, one of the major operational issues was the company’s inability to generate revenue due to the delay in semaglutide’s approval in Canada. The company was looking forward to the launch of this drug, which would have significantly helped it generate revenue.

•  Revenue Shortfall Due to Client Approval Delays: Besides the issue of semaglutide, the company also witnessed delays in the conversion of the company’s service agreement into a commercial supply agreement with one of the key customers. 
• Bearish Technical Indicators: From a technical standpoint, the stock has shown clear bearish signals. It is trading below key moving averages, such as the 50-day and 200-day, indicating a downtrend. Technical downgrades and negative momentum often trigger algorithmic and trader-driven selling, further pushing the price down. 
•  Downgrade by Analysts / Strong Sell Rating: The stock has also been downgraded to a “Strong Sell” rating by some analysts due to deteriorating fundamentals, weak profitability, and an expensive valuation relative to returns. Such downgrades influence institutional sentiment and can accelerate selling pressure. 

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

Onesource Specialty Pharma Recent Market Performance

The recent Onesource Specialty Pharma share price stands at ₹1,245.60, down 5.59% over the past day. The broader Sensex index also declined, though less severely, previously closed at 1,316.10, underscoring that Onesource Specialty Pharma movement was more acute than the general market trend. The Onesource Specialty Pharma share price has declined by 3.80% over the past month and by 28.69% over the past six months. The 52-week high of Onesource Specialty Pharma is ₹2,248.00, and the 52-week low of Onesource Specialty Pharma is ₹1,057.00. 

Note: For the live Onesource Specialty Pharma Share Price Target, visit the univest app and check the stock fundamentals.  

Onesource Specialty Pharma Share Price Target 

Onesource Specialty Pharma has an average share price target of 1,278.14. The consensus estimate represents an upside of 15.78% from the last price of 1,246.10. View the 14 reports from 8 analysts offering long-term price targets for Onesource Specialty Pharma. The consensus rating for Onesource Specialty Pharma is Neutral, based on insights from 12 analysts; 6 recommend buying, 3 suggest selling, and 3 recommend holding. Latest broker research reports have recommended buy, sell, and hold with the forecasted share price targets. 

Onesource Specialty Pharma Share Price Target 2026

As per the technical data, the minimum Onesource Specialty Pharma share price target is ₹1,278.14, and the maximum price that Onesource Specialty Pharma shares can reach is ₹1,298.56. 

Below are Onesource Specialty Pharma monthly share price targets for 2026; 

Summary of Onesource Specialty Pharma Share Price Target for 2026: 

• The initial Onesource Specialty Pharma share price target for 2026 was projected to be ₹1,254.70. 
• With favourable market conditions, the Onesource Specialty Pharma mid-year share price target could reach ₹1,275.10.
• By the end of 2026, the Onesource Specialty Pharma share price target is expected to reach ₹1,285.23, indicating bullish market trends in the near future. 

Onesource Specialty Pharma Share Price Target 2027

After using Fibonacci Projections, the estimated first half of the year Onesource Specialty Pharma share price target is expected to reach between ₹1242.23-₹1610.05, and the maximum value that shares of Onesource Specialty Pharma can reach is ₹1803.09. 

Below are the Onesource Specialty Pharma monthly share price targets for 2027; 

Summary of Onesource Specialty Pharma Share Price Target for 2027: 

• The initial Onesource Specialty Pharma share price target for 2027 was ₹1,454.03. 
• With favourable market conditions, the mid-year Onesource Specialty Pharma share price target could reach ₹1,610.05.
• By the end of 2027, the Onesource Specialty Pharma share price target is expected to reach ₹1,803.09, indicating bullish market trends in the near future. 

Summary of Onesource Specialty Pharma Share Price Target from 2026 to 2030 

Here’s the summary of the Onesource Specialty Pharma share price target from 2026 to 2030: 

Onesource Specialty Pharma: Analyst Rating 

• The average 12-month price target is ₹1,150.73, and the consensus rating is Hold (a mix of Buy, Hold, & Sell). 
• The analyst’s target range is between ₹1,150.73 and ₹1,426.99. 
• According to some analysts, concerns remain about a ‘Reduce’ call at 1,426.99. 
• The analyst’s sentiment is mixed; there have been recent bullish calls (ICICI, JM), but also cautious ones (Motilal Oswal, Nuvama). 

Note: For the live Onesource Specialty Pharma Share Price Target, visit the univest app and check the stock fundamentals.  

Onesource Specialty Pharma Future Outlook 

While the recent trading activity in Onesource Specialty Pharma highlights fluctuating volatility and investor interest, the prevailing downward price trend and volume concentration near lows suggest caution. Onesource Specialty Pharma is forecast to grow earnings and revenue by 115.8% and 42.7% per annum, respectively. EPS is expected to grow by 120.30% per annum. Return on equity is forecast to be 12.60% in 3 years. 

Investors and other market participants may find value in monitoring delivery volumes with the prevailing price movements. The bank has a high valuation, with a high Price-to-Book Value, leading to high market volatility relative to its risk-based assets. 

Also Read: Why is Rain Industries’ Share Price Falling? 

What is the Right Time to Buy Onesource Specialty Pharma Shares? 

According to analysts, the Onesource Specialty Pharma share price is determined by market factors. The share price has decreased due to internal company factors, as discussed above. Therefore, investors must review all relevant factors before investing in Onesource Specialty Pharma. There are some factors to consider before investing in Onesource Specialty Pharma shares.

• Strong Fundamentals: Investors should review Onesource Specialty Pharma Company’s fundamentals before investing. If a company has strong fundamentals, high profitability, and effective management, then investors should consider investing in it.    
• Financing Partnerships: Financing partnerships bridge the gap between customers and financial institutions, facilitating the distribution of a wide range of products and generating positive sales revenue for many consumers.   
• Growth in the Pharma sector: The company is well-positioned to deliver benefits to Onesource Specialty Pharma. This dominant sector increases demand and prices for Onesource Specialty Pharma.
• Highly Volatile: Prices are highly volatile, leading to significant price swings that substantially affect Onesource Specialty Pharma stock price. Investors must review the market structure before investing in Onesource Specialty Pharma Company shares. 

Note: For the live Onesource Specialty Pharma Share Price Target, visit the univest app and check the stock fundamentals. 

Conclusion 

To summarise, Onesource Specialty Pharma opened at ₹1,159.20, down 5.48% from the previous close, marking the lowest intraday level as well. The Onesource Specialty Pharma’ share performance underperformed both its sector and the broader market, continuing a sequence of declines over the recent sessions. Technical indicators predominantly point to a cautious market assessment, with the stock trading below all moving averages and exhibiting bearish momentum.   

FAQs

What are the key reasons behind the Onesource Specialty Pharma share price fall? 

There are several reasons behind the Onesource Specialty Pharma share price falling, including Weak Q3 FY26 Financial Results, Delay in Semaglutide Approval (Canada), Revenue Shortfall Due to Client Approval Delays, Bearish Technical Indicators, and  Downgrade by Analysts / Strong Sell Rating. However, one of the major operational issues was the company’s inability to generate revenue due to the delay in semaglutide’s approval in Canada.       

What is the Onesource Specialty Pharma share price target? 

Onesource Specialty Pharma has an average share price target of 1,278.14. The consensus estimate represents an upside of 15.78% from the last price of 1,246.10. View the 14 reports from 8 analysts offering long-term price targets for Onesource Specialty Pharma. The consensus rating for Onesource Specialty Pharma is Neutral, based on insights from 12 analysts; 6 recommend buying, 3 suggest selling, and 3 recommend holding.

What are the factors affecting Onesource Specialty Pharma shares? 

According to analysts, the Onesource Specialty Pharma share price is determined by market factors. The share price has decreased due to internal company factors, as discussed above. Therefore, investors must review all relevant factors before investing in Onesource Specialty Pharma. There are some factors to consider before investing in Onesource Specialty Pharma Company shares. Financing partnerships bridge the gap between customers and financial institutions, facilitating the distribution of a wide range of products and generating positive sales revenue for many consumers.

Is Onesource Specialty Pharma a good share to buy? 

While the recent trading activity in Onesource Specialty Pharma highlights fluctuating volatility and investor interest, the prevailing downward price trend and volume concentration near lows suggest caution. Investors and other market participants may find value in monitoring delivery volumes with the prevailing price movements. The bank has a high valuation, with a high Price-to-Book Value, leading to high market volatility relative to its risk-based assets. 

Also Read

Why is KRBL Share Price Falling? Check Next Share Price Target 

Why is Reliance Infrastructures Share Price Falling? Check Next Share Price Target 

Why is Mahanagar Gas Share Price Falling? Check Next Share Price Target 

Why is Happiest Minds Share Price Falling? Check Next Share Price Target